Literature DB >> 22765017

Phosphorylation of Munc18-1 by Dyrk1A regulates its interaction with Syntaxin 1 and X11α.

Jung-Hwa Park1, Min-Su Jung, Yeun-Soo Kim, Woo-Joo Song, Sul-Hee Chung.   

Abstract

Dual-specificity tyrosine(Y)-phosphorylation-regulated kinase 1A (Dyrk1A) is a protein kinase that might be responsible for mental retardation and early onset of Alzheimer's disease in Down's syndrome patients. Dyrk1A plays a role in many cellular pathways through phosphorylation of diverse substrate proteins; however, its role in synaptic vesicle exocytosis is poorly understood. Munc18-1, a central regulator of neurotransmitter release, interacts with Syntaxin 1 and X11α. Syntaxin 1 is a key soluble N-ethylmaleimide-sensitive factor attachment protein receptor protein involved in synaptic vesicle docking/fusion events, and X11α modulates amyloid precursor protein processing and β amyloid generation. In this study, we demonstrate that Dyrk1A interacts with and phosphorylates Munc18-1 at the Thr(479) residue. The phosphorylation of Munc18-1 at Thr(479) by Dyrk1A stimulated binding of Munc18-1 to Syntaxin 1 and X11α. Furthermore, the levels of phospho-Thr(479) -Munc18-1 were enhanced in the brains of transgenic mice over-expressing Dyrk1A protein, providing in vivo evidence of Munc18-1 phosphorylation by Dyrk1A. These results reveal a link between Munc18-1 and Dyrk1A in synaptic vesicle trafficking and amyloid precursor protein processing, suggesting that up-regulated Dyrk1A in Down's syndrome and Alzheimer's disease brains may contribute to some pathological features, including synaptic dysfunction and cognitive defect through abnormal phosphorylation of Munc18-1.
© 2012 The Authors. Journal of Neurochemistry © 2012 International Society for Neurochemistry.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22765017     DOI: 10.1111/j.1471-4159.2012.07861.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  8 in total

1.  Phosphorylation and inactivation of glycogen synthase kinase 3β (GSK3β) by dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A).

Authors:  Woo-Joo Song; Eun-Ah Christine Song; Min-Su Jung; Sun-Hee Choi; Hyung-Hwan Baik; Byung Kwan Jin; Jeong Hee Kim; Sul-Hee Chung
Journal:  J Biol Chem       Date:  2014-12-04       Impact factor: 5.157

2.  Impaired development of neocortical circuits contributes to the neurological alterations in DYRK1A haploinsufficiency syndrome.

Authors:  Juan Arranz; Elisa Balducci; Krisztina Arató; Gentzane Sánchez-Elexpuru; Sònia Najas; Alberto Parras; Elena Rebollo; Isabel Pijuan; Ionas Erb; Gaetano Verde; Ignasi Sahun; Maria J Barallobre; José J Lucas; Marina P Sánchez; Susana de la Luna; Maria L Arbonés
Journal:  Neurobiol Dis       Date:  2019-03-01       Impact factor: 5.996

Review 3.  Diverse exocytic pathways for mast cell mediators.

Authors:  Hao Xu; Na-Ryum Bin; Shuzo Sugita
Journal:  Biochem Soc Trans       Date:  2018-02-22       Impact factor: 5.407

4.  Enhancement of BACE1 Activity by p25/Cdk5-Mediated Phosphorylation in Alzheimer's Disease.

Authors:  Woo-Joo Song; Mi-Young Son; Hye-Won Lee; Hyemyung Seo; Jeong Hee Kim; Sul-Hee Chung
Journal:  PLoS One       Date:  2015-08-28       Impact factor: 3.240

5.  Bioactive marine drugs and marine biomaterials for brain diseases.

Authors:  Clara Grosso; Patrícia Valentão; Federico Ferreres; Paula B Andrade
Journal:  Mar Drugs       Date:  2014-05-02       Impact factor: 5.118

Review 6.  Dyrk1a from Gene Function in Development and Physiology to Dosage Correction across Life Span in Down Syndrome.

Authors:  Helin Atas-Ozcan; Véronique Brault; Arnaud Duchon; Yann Herault
Journal:  Genes (Basel)       Date:  2021-11-20       Impact factor: 4.096

7.  Network pharmacology identify intersection genes of quercetin and Alzheimer's disease as potential therapeutic targets.

Authors:  Caihui Wei; Shu Li; Yu Zhu; Wenzhi Chen; Cheng Li; Renshi Xu
Journal:  Front Aging Neurosci       Date:  2022-08-23       Impact factor: 5.702

8.  Dyrk1a gene dosage in glutamatergic neurons has key effects in cognitive deficits observed in mouse models of MRD7 and Down syndrome.

Authors:  Véronique Brault; Thu Lan Nguyen; Javier Flores-Gutiérrez; Giovanni Iacono; Marie-Christine Birling; Valérie Lalanne; Hamid Meziane; Antigoni Manousopoulou; Guillaume Pavlovic; Loïc Lindner; Mohammed Selloum; Tania Sorg; Eugene Yu; Spiros D Garbis; Yann Hérault
Journal:  PLoS Genet       Date:  2021-09-29       Impact factor: 5.917

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.